| A human IgG4 monoclonal antibody is being developed by LEO Pharma for the treatment of atopic dermatitis |
| Received its first approval on 22 June 2021 in the EU |
| Approved for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.